Literature DB >> 26526943

mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment.

Kenta Masui1, Webster K Cavenee2, Paul S Mischel2.   

Abstract

Metabolic reprogramming is a central hallmark of cancer, enabling tumor cells to obtain the macromolecular precursors and energy needed for rapid tumor growth. Understanding how oncogenes coordinate altered signaling with metabolic reprogramming and how cancer cells harness cellular metabolism and its metabolites for their survival may yield new insights into tumor pathogenesis. Here, we review the recently identified central regulatory role for mTORC2, a downstream effector of many cancer-causing mutations, in metabolic reprogramming and cancer drug resistance in glioblastoma. We further consider the emerging concept that mTORC2 may connect genetics with environmental alterations in brain cancer.
© 2015 International Society of Neuropathology.

Entities:  

Keywords:  drug resistance; glioblastoma; mTORC2; metabolic reprogramming; nutrient

Mesh:

Substances:

Year:  2015        PMID: 26526943      PMCID: PMC4636016          DOI: 10.1111/bpa.12307

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  38 in total

1.  Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Authors:  Kazuhiro Tanaka; Ivan Babic; David Nathanson; David Akhavan; Deliang Guo; Beatrice Gini; Julie Dang; Shaojun Zhu; Huijun Yang; Jason De Jesus; Ali Nael Amzajerdi; Yinan Zhang; Christian C Dibble; Hancai Dan; Amanda Rinkenbaugh; William H Yong; Harry V Vinters; Joseph F Gera; Webster K Cavenee; Timothy F Cloughesy; Brendan D Manning; Albert S Baldwin; Paul S Mischel
Journal:  Cancer Discov       Date:  2011-09-13       Impact factor: 39.397

2.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

3.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

4.  Transcriptional amplification in tumor cells with elevated c-Myc.

Authors:  Charles Y Lin; Jakob Lovén; Peter B Rahl; Ronald M Paranal; Christopher B Burge; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

5.  Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation.

Authors:  Joyce V Lee; Alessandro Carrer; Supriya Shah; Nathaniel W Snyder; Shuanzeng Wei; Sriram Venneti; Andrew J Worth; Zuo-Fei Yuan; Hee-Woong Lim; Shichong Liu; Ellen Jackson; Nicole M Aiello; Naomi B Haas; Timothy R Rebbeck; Alexander Judkins; Kyoung-Jae Won; Lewis A Chodosh; Benjamin A Garcia; Ben Z Stanger; Michael D Feldman; Ian A Blair; Kathryn E Wellen
Journal:  Cell Metab       Date:  2014-07-03       Impact factor: 27.287

6.  EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer.

Authors:  Ivan Babic; Erik S Anderson; Kazuhiro Tanaka; Deliang Guo; Kenta Masui; Bing Li; Shaojun Zhu; Yuchao Gu; Genaro R Villa; David Akhavan; David Nathanson; Beatrice Gini; Sergey Mareninov; Rui Li; Carolina Espindola Camacho; Siavash K Kurdistani; Ascia Eskin; Stanley F Nelson; William H Yong; Webster K Cavenee; Timothy F Cloughesy; Heather R Christofk; Douglas L Black; Paul S Mischel
Journal:  Cell Metab       Date:  2013-05-23       Impact factor: 27.287

7.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

8.  TORC2-a new player in genome stability.

Authors:  Ronit Weisman; Adiel Cohen; Susan M Gasser
Journal:  EMBO Mol Med       Date:  2014-08       Impact factor: 12.137

Review 9.  Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance.

Authors:  Si-Han Wu; Jun-Feng Bi; Timothy Cloughesy; Webster K Cavenee; Paul S Mischel
Journal:  Cancer Biol Med       Date:  2014-12       Impact factor: 4.248

10.  A drosophila model for EGFR-Ras and PI3K-dependent human glioma.

Authors:  Renee D Read; Webster K Cavenee; Frank B Furnari; John B Thomas
Journal:  PLoS Genet       Date:  2009-02-13       Impact factor: 5.917

View more
  12 in total

1.  Metabolic Reprogramming Mediated by the mTORC2-IRF4 Signaling Axis Is Essential for Macrophage Alternative Activation.

Authors:  Stanley Ching-Cheng Huang; Amber M Smith; Bart Everts; Marco Colonna; Erika L Pearce; Joel D Schilling; Edward J Pearce
Journal:  Immunity       Date:  2016-10-18       Impact factor: 31.745

2.  mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT.

Authors:  Yuchao Gu; Claudio P Albuquerque; Daniel Braas; Wei Zhang; Genaro R Villa; Junfeng Bi; Shiro Ikegami; Kenta Masui; Beatrice Gini; Huijun Yang; Timothy C Gahman; Andrew K Shiau; Timothy F Cloughesy; Heather R Christofk; Huilin Zhou; Kun-Liang Guan; Paul S Mischel
Journal:  Mol Cell       Date:  2017-06-22       Impact factor: 17.970

Review 3.  mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling.

Authors:  Kenta Masui; Noriyuki Shibata; Webster K Cavenee; Paul S Mischel
Journal:  Bioessays       Date:  2016-07-18       Impact factor: 4.345

4.  Metabolic Reprogramming in Brain Cancer: A Coordinated Effort.

Authors:  Sriram Venneti; Paul S Mischel
Journal:  Brain Pathol       Date:  2015-11       Impact factor: 6.508

Review 5.  mTOR-Dependent Cell Proliferation in the Brain.

Authors:  Larisa Ryskalin; Gloria Lazzeri; Marina Flaibani; Francesca Biagioni; Stefano Gambardella; Alessandro Frati; Francesco Fornai
Journal:  Biomed Res Int       Date:  2017-11-13       Impact factor: 3.411

Review 6.  Metabolic Reprogramming in Glioma.

Authors:  Marie Strickland; Elizabeth A Stoll
Journal:  Front Cell Dev Biol       Date:  2017-04-26

7.  Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma.

Authors:  Angelica Benavides-Serrato; Jihye Lee; Brent Holmes; Kenna A Landon; Tariq Bashir; Michael E Jung; Alan Lichtenstein; Joseph Gera
Journal:  PLoS One       Date:  2017-04-28       Impact factor: 3.240

Review 8.  Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function.

Authors:  Carla Garza-Lombó; María E Gonsebatt
Journal:  Front Cell Neurosci       Date:  2016-06-16       Impact factor: 5.505

9.  Hypoxia-induced release, nuclear translocation, and signaling activity of a DLK1 intracellular fragment in glioma.

Authors:  Elisa Stellaria Grassi; Vasiliki Pantazopoulou; Alexander Pietras
Journal:  Oncogene       Date:  2020-03-24       Impact factor: 9.867

Review 10.  mTOR Complexes as a Nutrient Sensor for Driving Cancer Progression.

Authors:  Mio Harachi; Kenta Masui; Yukinori Okamura; Ryota Tsukui; Paul S Mischel; Noriyuki Shibata
Journal:  Int J Mol Sci       Date:  2018-10-21       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.